A Phase II Study of T-DXd Plus Stereotactic Radiotherapy(SRT) in HER2-positive Breast Cancer Brain Metastases
A Phase II Study of T-DXd Plus Stereotactic Radiotherapy(SRT) in HER2-positive Breast Cancer Brain Metastases
This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.
Inclusion Criteria:
Pathologically confirmed HER2 positive advanced breast cancer
Age>18 years.
Brain metastases confirmed by enhanced brain MRI. Metastases number less than 15.
KPS≥70 or KPS ≥60 with neurologic symptoms caused by BM
Life expectancy of more than 6 months
Prior therapy of oral dexamethasone not exceeding 16mg/d
Time interval from prior therapy was more than 2 weeks, and evaluation of adverse events is no more than grade 1.
Screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration):
Signed the informed consent form prior to patient entry
Exclusion Criteria:
yzzhi2014@163.com+8618017317126